Cumberland Pharmaceuticals Inc. has announced a strategic partnership with RedHill Biopharma Ltd. to jointly commercialize Talicia®, an FDA-approved oral therapy for Helicobacter pylori infection in adults. Under the agreement, the two companies will form a new jointly owned entity, with RedHill contributing all Talicia assets, including its international licenses, and Cumberland providing $4 million in investment capital. Cumberland will take responsibility for the product's distribution and sales, leveraging its national field sales force to expand Talicia's reach. Both companies will equally share net revenues and collaborate on operational aspects such as sales, marketing, manufacturing, regulatory, and supply chain functions. Talicia is patent protected through 2042 and holds eight years of U.S. market exclusivity under the Qualified Infectious Disease Product (QIDP) designation.